Effects of Chronic Insomnia on the Neuroendocrine Regulation of Glucose and Lipid Metabolism

• Diabetes mellitus
• Known other sleep disorders, such as depression, obstructive sleep apnea and restless legs syndrome
• Alcohol consumption \> 40 g / d in males, \> 20 g / d in females, respectively,
• Patients treated with medications potentially interfering with glucose metabolism, such as systemic steroids, immunosuppressive drugs (cyclosporine, tacrolimus, sirolimus), highly active antiretroviral therapy, hydrochlorothiazide \> 25 mg/d
• Patients treated with lipid lowering drugs such as statins, fibrates, nicotinic acid derivatives, resins and ezetimibe in whom the lipid lowering therapy cannot be safely withheld for the duration of the study.
• Patients with LDL-cholesterol concentrations \> 4.9 mmol/l and fasting triglyceride concentrations \> 12 mmol/l.
• Any significant or unstable hepatic, cardiac, pulmonary, renal, neurological, musculoskeletal, hematological or endocrine disease.
• Pregnant or Breast Feeding women
• Woman of childbearing potential not using a reliable method of birth control such as oral contraceptives or IUD.
• History of claustrophobia
• Ferromagnetic implants including pacemakers.
• Subjects refusing or unable to give written informed consent

Contact the study team to confirm eligibility.